Patrick Wilmerding

Irresistible Materials Ltd. develops next generation of photo-resist materials the semiconductor industry. The firm's photo-resist is a material that undergoes a change in its physical and chemical properties upon exposure to radiation that allows for the formation of a relief pattern in a material. The company was founded by Elwyn Shelley, Alex Robinson and David Alexander Ure in 2010 and is headquartered in Swansea Waterfront, the United Kingdom.

Rafael Pharmaceuticals, Inc. develops anti-cancer drug delivery technology. It produces highly selective and effective anti-cancer agents with minimal toxic effects on normal cells and tissues by attacking regulatory processes that are unique to cancer and not found in healthy cells. The firm would ensure a significant improvement in the safety profile of cancer treatment. The firm provides CPI-613, Altered Energy Metabolism Directed (AEMD) platform, targets enzymes that are involved in cancer cell energy metabolism and are located in the mitochondria of cancer cells. The company was founded by Robert G. L. Shorr and is headquartered in Cranbury, NJ.

Rafael Pharmaceuticals, Inc. develops anti-cancer drug delivery technology. It produces highly selective and effective anti-cancer agents with minimal toxic effects on normal cells and tissues by attacking regulatory processes that are unique to cancer and not found in healthy cells. The firm would ensure a significant improvement in the safety profile of cancer treatment. The firm provides CPI-613, Altered Energy Metabolism Directed (AEMD) platform, targets enzymes that are involved in cancer cell energy metabolism and are located in the mitochondria of cancer cells. The company was founded by Robert G. L. Shorr and is headquartered in Cranbury, NJ.

Rafael Pharmaceuticals, Inc. develops anti-cancer drug delivery technology. It produces highly selective and effective anti-cancer agents with minimal toxic effects on normal cells and tissues by attacking regulatory processes that are unique to cancer and not found in healthy cells. The firm would ensure a significant improvement in the safety profile of cancer treatment. The firm provides CPI-613, Altered Energy Metabolism Directed (AEMD) platform, targets enzymes that are involved in cancer cell energy metabolism and are located in the mitochondria of cancer cells. The company was founded by Robert G. L. Shorr and is headquartered in Cranbury, NJ.

Rafael Pharmaceuticals, Inc. develops anti-cancer drug delivery technology. It produces highly selective and effective anti-cancer agents with minimal toxic effects on normal cells and tissues by attacking regulatory processes that are unique to cancer and not found in healthy cells. The firm would ensure a significant improvement in the safety profile of cancer treatment. The firm provides CPI-613, Altered Energy Metabolism Directed (AEMD) platform, targets enzymes that are involved in cancer cell energy metabolism and are located in the mitochondria of cancer cells. The company was founded by Robert G. L. Shorr and is headquartered in Cranbury, NJ.

Irresistible Materials Ltd. develops next generation of photo-resist materials the semiconductor industry. The firm's photo-resist is a material that undergoes a change in its physical and chemical properties upon exposure to radiation that allows for the formation of a relief pattern in a material. The company was founded by Elwyn Shelley, Alex Robinson and David Alexander Ure in 2010 and is headquartered in Swansea Waterfront, the United Kingdom.

Irresistible Materials Ltd. develops next generation of photo-resist materials the semiconductor industry. The firm's photo-resist is a material that undergoes a change in its physical and chemical properties upon exposure to radiation that allows for the formation of a relief pattern in a material. The company was founded by Elwyn Shelley, Alex Robinson and David Alexander Ure in 2010 and is headquartered in Swansea Waterfront, the United Kingdom.

Rafael Pharmaceuticals, Inc. develops anti-cancer drug delivery technology. It produces highly selective and effective anti-cancer agents with minimal toxic effects on normal cells and tissues by attacking regulatory processes that are unique to cancer and not found in healthy cells. The firm would ensure a significant improvement in the safety profile of cancer treatment. The firm provides CPI-613, Altered Energy Metabolism Directed (AEMD) platform, targets enzymes that are involved in cancer cell energy metabolism and are located in the mitochondria of cancer cells. The company was founded by Robert G. L. Shorr and is headquartered in Cranbury, NJ.

Irresistible Materials Ltd. develops next generation of photo-resist materials the semiconductor industry. The firm's photo-resist is a material that undergoes a change in its physical and chemical properties upon exposure to radiation that allows for the formation of a relief pattern in a material. The company was founded by Elwyn Shelley, Alex Robinson and David Alexander Ure in 2010 and is headquartered in Swansea Waterfront, the United Kingdom.

Irresistible Materials Ltd. develops next generation of photo-resist materials the semiconductor industry. The firm's photo-resist is a material that undergoes a change in its physical and chemical properties upon exposure to radiation that allows for the formation of a relief pattern in a material. The company was founded by Elwyn Shelley, Alex Robinson and David Alexander Ure in 2010 and is headquartered in Swansea Waterfront, the United Kingdom.

Irresistible Materials Ltd. develops next generation of photo-resist materials the semiconductor industry. The firm's photo-resist is a material that undergoes a change in its physical and chemical properties upon exposure to radiation that allows for the formation of a relief pattern in a material. The company was founded by Elwyn Shelley, Alex Robinson and David Alexander Ure in 2010 and is headquartered in Swansea Waterfront, the United Kingdom.

Rafael Pharmaceuticals, Inc. develops anti-cancer drug delivery technology. It produces highly selective and effective anti-cancer agents with minimal toxic effects on normal cells and tissues by attacking regulatory processes that are unique to cancer and not found in healthy cells. The firm would ensure a significant improvement in the safety profile of cancer treatment. The firm provides CPI-613, Altered Energy Metabolism Directed (AEMD) platform, targets enzymes that are involved in cancer cell energy metabolism and are located in the mitochondria of cancer cells. The company was founded by Robert G. L. Shorr and is headquartered in Cranbury, NJ.

Rafael Pharmaceuticals, Inc. develops anti-cancer drug delivery technology. It produces highly selective and effective anti-cancer agents with minimal toxic effects on normal cells and tissues by attacking regulatory processes that are unique to cancer and not found in healthy cells. The firm would ensure a significant improvement in the safety profile of cancer treatment. The firm provides CPI-613, Altered Energy Metabolism Directed (AEMD) platform, targets enzymes that are involved in cancer cell energy metabolism and are located in the mitochondria of cancer cells. The company was founded by Robert G. L. Shorr and is headquartered in Cranbury, NJ.

Rafael Pharmaceuticals, Inc. develops anti-cancer drug delivery technology. It produces highly selective and effective anti-cancer agents with minimal toxic effects on normal cells and tissues by attacking regulatory processes that are unique to cancer and not found in healthy cells. The firm would ensure a significant improvement in the safety profile of cancer treatment. The firm provides CPI-613, Altered Energy Metabolism Directed (AEMD) platform, targets enzymes that are involved in cancer cell energy metabolism and are located in the mitochondria of cancer cells. The company was founded by Robert G. L. Shorr and is headquartered in Cranbury, NJ.